About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  About Us
  Research & Development
  Branded Formulations
  Financial Results
  - Earnings call transcript Q1FY17
  - Investor Presentation
  - Chairman's AGM 2016 Speech
  - Annual Reports
  Facilities Virtual Tour
  - Biocon Profile
  - CMD Profile
  - Video Gallery

 Annual Report 2016


 Biocon Malaysia

 Biocon Academy



At Biocon, we are driven by our passion to develop research - driven cutting edge therapies. Our tryst with innovation has enabled us to address the relatively unmet needs of our patients through differentiated products in challenging therapeutic spaces. We have earned the trust of patients and doctors through our products that are safe, efficacious and affordable. We are constantly engaged in pursuit of excellence to find solutions that heal the world.

Biocon is India's largest and fully-integrated, innovation-led biopharmaceutical company. We are committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer.

Through innovative products and research services we are constantly enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. We have successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'.
Some of our key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb(Itolizumab), a 'first in class' anti-CD6 monoclonal antibody.

We have a rich pipeline of biosimilars and novel biologics at various stages of development including a high potential Insulin Tregopil.

As the largest Indian Insulins Company, we believe we have made a huge difference to millions of diabetic patients in India. Over the years Biocon has also emerged as a leading Indian oncology company making cancer-care 'affordable' and 'accessible' to patients in India.





Q1FY17 Highlights
Stock Update

  Latest Press Release

 Aug. 25, 2016:
 Mylan and Biocon Announce  Regulatory Submission for  Proposed Biosimilar  Trastuzumab Accepted for  Review by European  Medicines Agency 

 July 28, 2016:
 Biocon Initiates "EK  Prayaas" Nationwide  Awareness  Program on  Hepatitis C

 July 21, 2016:
 Biocon Reports a Strong  Q1FY17
 Revenues at Rs 952 Crore, up  by 11 %; EBITDA Up 15% to Rs  271 Crore; Net Profit Up 17% at  Rs 147 Crore

  Media Coverage

August, 2016:
'We have enhanced patient access to insulin across India' - Kiran Mazumdar Shaw

July, 2016:
'We need meritocracy, not mediocrity' - Kiran Mazumdar Shaw








Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2016, Biocon. All Rights Reserved